The company's biosciences segment had revenues of $181 million, up 15 percent over the year-ago period's $157 million. The rise in revenues was attributed primarily to sales of the company's FacsCanto analyzer, and the FacsAria cell sorter, and sales of flow cytometry reagents to the clinical and research markets.
BD Medical had sales of $694 million, up 11 percent over the year-ago period's $627 million in revenue, while BD Diagnostics had sales of $414 million, up 3 percent over the previous period's $401 million in sales.
R&D expenditures were up 6.5 percent to $62 million for the period, compared to $58 million last year.
BD's operating income for the quarter was $250 million, up 48 percent over $168 million in Q1 FY '04.